PCSK9 Antagonists: Clinical Efficacy and Main Trends in the Development of New Medicines

MLA

A. A. Nekipelova, and R. N. Alyautdin. “PCSK9 Antagonists: Clinical Efficacy and Main Trends in the Development of New Medicines.” Безопасность и Риск Фармакотерапии, vol. 11, no. 3, Sept. 2023, pp. 279–91. EBSCOhost, https://doi.org/10.30895/2312-7821-2023-11-3-279-291.

APA

A. A. Nekipelova, & R. N. Alyautdin. (2023). PCSK9 Antagonists: Clinical Efficacy and Main Trends in the Development of New Medicines. Безопасность и Риск Фармакотерапии, 11(3), 279–291. https://doi.org/10.30895/2312-7821-2023-11-3-279-291

Chicago

A. A. Nekipelova, and R. N. Alyautdin. 2023. “PCSK9 Antagonists: Clinical Efficacy and Main Trends in the Development of New Medicines.” Безопасность и Риск Фармакотерапии 11 (3): 279–91. doi:10.30895/2312-7821-2023-11-3-279-291.